| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating activities | ||||||||||||
Net loss | ||||||||||||
-11,610 | -10,958 | -9,870 | -10,563 | -9,405 | -9,334 | -7,657 | -7,343 | -7,202 | -7,382 | -6,614 | -6,632 | -6,391 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||
Depreciation and amortization expense | ||||||||||||
1,046 | 821 | 1,235 | 544 | 409 | 332 | 411 | 337 | 272 | 145 | 122 | 111 | 104 |
Inventory step-up amortization | ||||||||||||
438 | - | - | - | - | - | - | - | - | - | - | - | - |
Stock-based compensation expense | ||||||||||||
2,109 | 1,675 | 1,828 | 1,601 | 1,284 | 1,491 | 1,867 | 890 | 636 | 737 | 623 | 550 | 258 |
Non-cash interest expense | ||||||||||||
22 | 21 | 22 | 22 | 24 | 37 | 34 | 46 | 53 | 55 | 54 | 54 | 75 |
Loss on disposal of fixed assets | ||||||||||||
-69 | - | - | - | - | - | - | - | - | - | - | - | - |
Change in fair value of preferred stock warrants | ||||||||||||
- | - | - | - | - | - | - | - | - | 152 | -31 | -99 | 68 |
Changes in operating assets and liabilities: | ||||||||||||
Accounts receivable | ||||||||||||
1,174 | -1,109 | 2,178 | 1,831 | 465 | 2,143 | 1,063 | -1,075 | -1,148 | 1,395 | 1,078 | -527 | -264 |
Prepaid expenses and other assets | ||||||||||||
495 | -393 | 406 | -160 | -142 | 1,075 | 72 | -242 | 923 | -85 | 138 | -33 | 253 |
Inventory | ||||||||||||
1,398 | -496 | 1,038 | 1,107 | 1,798 | 627 | -111 | 154 | 933 | 1,008 | 325 | 545 | 165 |
Other non-current assets | ||||||||||||
-32 | 0 | 23 | 1 | -3 | - | - | - | - | - | - | - | - |
Accounts payable | ||||||||||||
-1,145 | 1,456 | 765 | -279 | -1,321 | 1,166 | 778 | 51 | -677 | 306 | 1,257 | -146 | -414 |
Accrued compensation and benefits, other accrued expenses and other current liabilities | ||||||||||||
-1,710 | 249 | -96 | 996 | -327 | 1,156 | 902 | 947 | -1,904 | 691 | 179 | 754 | 411 |
Contract acquisition costs | ||||||||||||
-110 | -197 | 593 | -35 | -25 | - | - | - | - | - | - | - | - |
Operating lease liabilities | ||||||||||||
253 | - | - | - | - | - | - | - | - | - | - | - | - |
Other non-current liabilities | ||||||||||||
-177 | -223 | 620 | 3,366 | 6,082 | - | - | - | - | - | - | - | - |
Deferred revenue | ||||||||||||
671 | -104 | -294 | -355 | 45 | 604 | -1,922 | 0 | -531 | 1,173 | -326 | -3 | 2,051 |
Net cash used in operating activities | ||||||||||||
-13,179 | -4,535 | -8,832 | -7,468 | -5,352 | -8,108 | -6,643 | -3,909 | -10,061 | -4,402 | -7,485 | -6,227 | -3,992 |
Investing activities | ||||||||||||
Purchases of property and equipment | ||||||||||||
426 | 544 | 473 | 3,913 | 5,917 | 121 | 707 | 242 | 448 | 339 | 130 | 496 | 167 |
Acquisition of UmanDiagnostics AB, net of cash acquired | ||||||||||||
- | - | - | - | - | 1 | 799 | 0 | 3,001 | - | - | - | - |
Net cash used in investing activities | ||||||||||||
-426 | -544 | -15,002 | -3,913 | -5,917 | -107 | -1,656 | -242 | -3,449 | -339 | -130 | -496 | -167 |
Financing activities | ||||||||||||
Proceeds from sale of preferred stock, net of issuance costs | ||||||||||||
- | - | - | - | - | - | - | - | -53 | - | - | - | - |
Proceeds from exercise of stock warrants | ||||||||||||
- | - | - | - | - | - | - | - | - | 28 | 0 | 0 | 1 |
Proceeds from stock options exercised | ||||||||||||
496 | 644 | 266 | 1,407 | 503 | 1,187 | 303 | 297 | 84 | 130 | 12 | 30 | 30 |
Proceeds from ESPP purchase | ||||||||||||
440 | 80 | 406 | 65 | 328 | - | - | - | - | - | - | - | - |
Proceeds from the issuance of notes payable and warrants, net of issuance costs | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | -59 |
Payments on notes payable | ||||||||||||
75 | - | - | - | - | -1 | 55 | 903 | 972 | - | - | 0 | 921 |
Net cash provided by financing activities | ||||||||||||
861 | 724 | 65,201 | 49,441 | 831 | 1,221 | 248 | -606 | -941 | 65,733 | 12 | 8,453 | -949 |
Net decrease in cash and cash equivalents | ||||||||||||
-12,744 | -4,355 | 41,367 | 38,060 | -10,438 | -6,994 | -8,051 | -4,757 | -14,451 | - | - | - | - |
Effect of foreign currency exchange rate on cash | ||||||||||||
-78 | - | - | - | - | - | - | - | - | - | - | - | - |
Supplemental cash flow information | ||||||||||||
Accretion of preferred stock to redemption value | ||||||||||||
- | - | - | - | - | - | - | - | - | 809 | 1,112 | 1,099 | 1,090 |
Cash paid for interest | ||||||||||||
155 | 178 | 318 | 0 | 160 | 100 | 159 | 166 | 181 | 183 | 185 | 185 | 190 |
Warrants issued to lenders | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 119 |
Purchases of property and equipment included in accounts payable | ||||||||||||
102 | 119 | -234 | 268 | 11 | - | - | - | - | - | 191 | 7 | 79 |
Reconciliation of cash, cash equivalents, and restricted cash: | ||||||||||||
Net decrease in cash and cash equivalents | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | -5,108 |